TrialJournal for immunotherapy of cancer2022

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.

Haiping Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.